Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder

被引:47
作者
Thomas, Anil A. [2 ]
Stephenson, Andrew J. [2 ,3 ]
Campbell, Steven C. [2 ,3 ]
Jones, J. Stephen [2 ]
Hansel, Donna E. [1 ,2 ,3 ]
机构
[1] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44195 USA
[2] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44195 USA
[3] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA
关键词
Bladder neoplasms; Urachus; Adenocarcinoma; Signet-ring cell carcinoma; Cystectomy; Treatment outcome; Immunohistochemistry; Clinicopathologic; TERM FOLLOW-UP; URINARY-BLADDER; INTESTINAL METAPLASIA; BETA-CATENIN; CARCINOMA; CANCER; URACHAL; TRACT; DIFFERENTIATION; DISTINCTION;
D O I
10.1016/j.humpath.2008.06.022
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Signet-ring adenocarcinoma is an aggressive form of primary bladder adenocarcinoma that has been associated with poor outcomes. The utility of immunohistochemical markers in tumors with signet-ring morphology may vary from more typical adenocarcinomas arising at the same location, although this has not been examined in bladder adenocarcinoma. We examined a series of bladder adenocarcinomas to determine the impact of signet-ring cell features on clinical outcomes and immunohistochemical findings. We identified 25 patients with bladder adenocarcinoma, ranging in age from 28 to 78 years (mean, 57 years) and with a male-female ratio of 18:7. Six cases were urachal in origin. Signet-ring cells occurred in 19 of 25 bladder adenocarcinomas (76%) and ranged from 5% to 100% of tumor volume, with most tumors demonstrating more than 60% signet-ring cell differentiation (15/19), when present. Regional lymph node metastases were present in 8 of 19 patients (42%) who underwent cystectomy. The percentage of tumor containing signet-ring cells was significantly associated with the presence of adverse pathologic-features (defined as unresectable primary tumor or regional lymph node metastasis, P = .013) and decreased overall Survival (P = .034), and the latter remained significant in multivariable analysis after adjusting for positive soft tissue margins (P = .026). A comparison between immunohistochemical markers frequently used to analyze bladder adenocarcinoma demonstrated decreased expression of several markers in signet-ring (n=9) versus colonic-type (n=8) morphology, including CDX-2, beta-catenin, and E-cadherin, although these results did not reach statistical significance. In summary, the extent of signet-ring differentiation in bladder adenocarcinoma is associated with worsened survival and higher stage disease; the utility of immunohistochemical analysis in foci consisting of predominant signet-ring cells may be limited, although further studies that address this finding are needed. (c) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:108 / 116
页数:9
相关论文
共 37 条
[1]   PRIMARY SIGNET RING CELL ADENOCARCINOMA OF THE BLADDER [J].
BLUTE, ML ;
ENGEN, DE ;
TRAVIS, WD ;
KVOLS, LK .
JOURNAL OF UROLOGY, 1989, 141 (01) :17-21
[2]  
BULLOCK PS, 1987, CANCER-AM CANCER SOC, V59, P2086, DOI 10.1002/1097-0142(19870615)59:12<2086::AID-CNCR2820591220>3.0.CO
[3]  
2-J
[4]   Hepatoid adenocarcinoma of the urinary bladder -: An unusual neoplasm [J].
Burgués, O ;
Ferrer, J ;
Navarro, S ;
Ramos, D ;
Botella, E ;
Llombart-Bosch, A .
VIRCHOWS ARCHIV, 1999, 435 (01) :71-75
[5]   ADENOCARCINOMA OF URINARY-BLADDER - CLASSIFICATION AND MANAGEMENT [J].
BURNETT, AL ;
EPSTEIN, JI ;
MARSHALL, FF .
UROLOGY, 1991, 37 (04) :315-321
[6]   E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup [J].
Byrne, RA ;
Shariat, SF ;
Brown, R ;
Kattan, MW ;
Morton, RA ;
Wheeler, TM ;
Lerner, SP .
JOURNAL OF UROLOGY, 2001, 165 (05) :1473-1479
[7]  
CHOI HY, 1984, CANCER-AM CANCER SOC, V53, P1985, DOI 10.1002/1097-0142(19840501)53:9<1985::AID-CNCR2820530930>3.0.CO
[8]  
2-Z
[9]  
CHOR PJ, 1993, MODERN PATHOL, V6, P225
[10]   Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon [J].
Chu, PG ;
Weiss, LM .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (06) :884-892